Immune Treatments After Failed IVF: What the Evidence Supports
Key Takeaways
The immune system helps implantation, but a negative transfer does not prove that the body rejected an embryo. Routine NK panels and treatments such as intralipids, IVIG, PBMC or steroids still lack a reliable live-birth benefit for everyday use. A clearer next step is usually a careful review of embryos, uterus, transfer technique and hormones—before adding another drug.
Key evidence: ASRM committee opinion on recurrent implantation failure (2026) ESHRE good practice recommendations on recurrent implantation failure (2023) Prednisone versus placebo randomized trial (JAMA, 2023)
After more than one unsuccessful embryo transfer, many people ask: “Could my immune system be rejecting the embryo?” It is an understandable question. It also offers a tidy explanation for a painful event that often has no single cause.
The biology is less tidy. Immune cells help with normal implantation; their presence does not mean the embryo is under attack. A commercially labelled “abnormal” result is not, by itself, proof of why a transfer failed—and it does not automatically name a treatment that will improve live birth.
On this page
- Does the immune system reject an embryo?
- What do immune tests actually show?
- Do intralipids, IVIG, steroids or PBMC improve live birth?
- Why do some studies look positive?
- What should be reviewed before another transfer?
- When does a specialist immune assessment make sense?
- Clinical note
- Questions to ask before accepting an add-on
- Frequently asked questions
Does the Immune System Reject an Embryo?
Short answer: Normal implantation needs carefully coordinated immune activity. That is not the same as rejecting a transplanted organ.
Uterine natural killer (NK) cells are a normal part of the endometrium and change across the menstrual cycle. Their name often causes alarm, yet blood NK cells and uterine NK cells are not interchangeable. The HFEA’s patient evidence review explains that blood NK measurements do not give useful information about pregnancy outcomes, and that uterine NK-cell testing remains a research question.
One or two unsuccessful transfers also should not be labelled an immune disorder. ASRM’s 2026 committee opinion defines recurrent implantation failure using the cumulative chance expected from the number and quality of blastocysts transferred—not a fixed number that fits every patient. Age, embryo ploidy, embryo quality and prior transfer history all change that calculation.
Repeated implantation failure is different from recurrent pregnancy loss. In implantation failure, the pregnancy test stays negative after transfer. In pregnancy loss, implantation has occurred and the pregnancy is then lost. The two can overlap in real life, but they do not justify the same tests or treatments.
What Do Immune Tests Actually Show?
Short answer: Most commercially offered panels measure a laboratory marker or an association—not a validated cause of failed implantation.
Tests may include peripheral-blood NK-cell number or activity, uterine NK cells, Th1/Th2 cytokine ratios, broader cytokine panels or HLA compatibility. A laboratory can produce a number. The harder questions are whether that number reliably predicts live birth, and whether changing it improves the outcome.
The ESHRE good practice recommendations do not recommend routine peripheral or uterine NK-cell testing, uterine T-cell assessment, blood cytokine testing or HLA-C compatibility testing in recurrent implantation failure. Reasons include uncertain reference ranges, poor standardisation, differences between blood and endometrial biology, and no proven treatment pathway linked to the result.
An “abnormal” result can therefore feel more certain than it is. A value outside one laboratory’s range may not have caused the failed transfer. Before paying for a panel, ask what decision the result would change—and whether that change has been shown to improve live birth.
Do Intralipids, IVIG, Steroids or PBMC Improve Live Birth?
Short answer: Some small studies and meta-analyses report better pregnancy outcomes. Current major guidance does not consider that evidence reliable enough for routine use.
| Add-on | What the evidence currently says | Practical interpretation |
|---|---|---|
| Steroids such as prednisone | In a double-blind randomized trial of 715 women with at least two failed transfers, live birth was 37.8% with prednisone and 38.8% with placebo. The trial also found signals of more biochemical pregnancy loss and preterm delivery in the prednisone group. | The JAMA trial does not support routine 10 mg prednisone for this indication. |
| Intralipid infusion | Results are inconsistent and moderate- or high-quality evidence is insufficient. | HFEA rates intralipids grey, meaning “not enough evidence to rate”—not proven benefit and not the same as proven no effect. ASRM 2026 also finds insufficient evidence for use in recurrent implantation failure. |
| IVIG | Observational studies and some pooled analyses report benefit, but populations and protocols vary; robust randomized evidence for live birth remains inadequate. | ESHRE and ASRM do not recommend IVIG for routine recurrent implantation failure care. HFEA gives it a red rating because of safety concerns. |
| PBMC or G-CSF | Small trials and pooled analyses sometimes suggest higher pregnancy rates, but definitions, preparation methods and safety reporting are inconsistent. | ESHRE does not recommend routine PBMC infusion or G-CSF while these uncertainties remain. |
| Heparin or aspirin without a diagnosed indication | These drugs target clotting rather than a vague “immune imbalance.” | ASRM does not recommend heparin or low-molecular-weight heparin to improve live birth in recurrent implantation failure without a separate indication. |
The outcome that matters is live birth—not a shifting blood marker, and not only an early positive test. Before accepting an add-on, ask whether it has improved that outcome in patients like you, and at what safety cost.
Why Do Some Studies Look Positive?
Short answer: A promising pooled result can sit alongside a cautious guideline when the underlying trials are small, overlapping or clinically different.
A 2025 umbrella review of randomized-trial reviews found positive signals for several interventions, including intralipid and PBMC. It also found that 41 of 47 included systematic reviews were of low or critically low methodological quality, with inconsistent definitions of recurrent implantation failure and overlapping trials. The authors therefore urged caution despite the direction of some estimates.
A newer systematic review of 77 immunological-intervention studies reached a more restrained conclusion: small samples and heterogeneous diagnostic criteria still prevent routine clinical use. That is why “a meta-analysis was positive” is not the end of the discussion. The result depends on which patients were included, how failure was defined, what other treatments were given, and whether live birth—not only implantation or clinical pregnancy—was measured.
What Should Be Reviewed Before Another Transfer?
Short answer: Start with a structured look at the embryos, uterus, transfer and hormone plan. Do not begin by assuming an immune cause.
A useful review may include:
- the number, developmental stage and quality of embryos transferred, along with age at egg retrieval;
- whether embryo ploidy information exists and what it would—or would not—change;
- laboratory development, freezing and thawing history;
- the uterine cavity and tubes, including whether repeat imaging is justified;
- endometrial thickness, progesterone exposure and transfer timing;
- whether the transfer was technically difficult;
- endometriosis, adenomyosis or chronic endometritis when the history or findings make them plausible;
- and the original infertility diagnosis, including relevant sperm factors.
This is not a list of tests every patient must complete. ASRM notes that if a careful review finds no clear correctable cause, more testing is not automatically useful—and another embryo transfer can still be reasonable, because many patients conceive later without an “immune” explanation.
PGT-A needs plain speaking too. ASRM 2026 says it may be discussed when previous embryos were untested, but there is no evidence that PGT-A itself raises live birth in recurrent implantation failure. Hysteroscopy helps when the cavity needs a closer look; it is not a default next step after every failed transfer.
For a broader step-by-step review, see what to assess after a failed IVF cycle. Questions about other add-ons are covered in our evidence summaries on EmbryoGlue and ERA testing.
When Does a Specialist Immune Assessment Make Sense?
Short answer: Assess a known or suspected immune disease on its own medical merits—not because a transfer failed or an NK result was high.
If you already have a diagnosed autoimmune disease, symptoms suggesting systemic illness, a personal history of thrombosis, or a pattern that raises concern for antiphospholipid syndrome, the relevant specialist should be involved. That is different from giving immunosuppression “empirically” to an otherwise healthy IVF patient.
Patients with a genuine immune condition should keep medically indicated steroids, biologic drugs or IVIG; those decisions belong to the physicians managing the disease, in coordination with reproductive medicine. Patients without that diagnosis should not receive the same medicines simply to cover an unproven theory. The clinical detail of when I seek rheumatology or immunology input is in the note below.
Clinical Note
The misconception I hear most often is this: “My NK cells came back high, so my immune system must be attacking the embryo and needs to be suppressed.”
Blood NK cells and uterine NK cells are not the same thing. Uterine NK cells have a normal job in implantation. An “elevated NK” result alone does not reliably tell us who will benefit from intralipid, IVIG or steroids. That is why I do not recommend those treatments solely after a failed transfer, a miscarriage, or a high NK number. ESHRE also does not recommend routine NK testing, intralipid or IVIG for this indication.
And these are not “harmless just-in-case” extras. Steroids can raise blood sugar and infection risk. IVIG can cause allergic reactions, clotting problems or kidney injury.
When do I ask for rheumatology or immunology help? When there is a known autoimmune disease, a previous blood clot, recurrent pregnancy loss with antiphospholipid antibodies, or systemic clues such as joint swelling, prolonged morning stiffness, mouth ulcers, photosensitivity, Raynaud phenomenon, an unexplained rash, low platelets or kidney findings. After two or more pregnancy losses, looking specifically for antiphospholipid syndrome can make sense.
The aim is not to blunt the immune system in the dark. If a real disease is present, treat that disease—with the right specialist, and with evidence.
— Dr. Senai Aksoy
Questions to Ask Before Accepting an Add-on
Short answer: Ask for the diagnosis, the live-birth evidence that applies to you, and the safety or cost that comes with uncertainty.
- What specific diagnosis is this treatment meant to treat?
- Is the proposed test validated for implantation outcomes, and how would its result change care?
- What is the absolute live-birth benefit in patients like me—not only the implantation or pregnancy rate?
- Is the treatment recommended by ASRM or ESHRE, or is it being offered as experimental care?
- What are the infusion, infection, allergy, clotting, kidney or pregnancy-related risks?
- Would the same budget and time be better used for another evidence-based transfer or a targeted reassessment?
These medicines are not empty add-ons. Steroids can raise infection, glucose and blood-pressure risks. IVIG can cause infusion reactions, thrombosis or kidney injury. Intralipid can trigger allergic or infusion reactions. The HFEA review treats the weak evidence for intralipid separately from the safety concerns that give steroids and IVIG a red rating.
Frequently Asked Questions
Does one failed embryo transfer mean I have an immune problem?
No. A failed transfer is common. On its own, it does not establish recurrent implantation failure or an immune diagnosis. The embryo, uterus, transfer and treatment context matter.
Is a high NK-cell result proof that my body rejected the embryo?
No. Blood and uterine NK cells differ. Reference ranges are not well standardised for this purpose. An abnormal result does not prove causation.
Is intralipid proven not to work?
Not quite. The honest problem today is softer than that slogan: we still lack reliable live-birth evidence for routine use. Research may yet identify a carefully defined subgroup. Until then, “try it because it might help” is not the same as good practice.
Is IVIG safer because it is used in other medical conditions?
No. IVIG can be appropriate and valuable for specific immune diseases. That does not establish benefit as an IVF add-on. It is a donor-derived blood product with real risks and limited supply.
Should I take prednisone “just in case” before transfer?
Routine use is not supported. In the largest cited randomized trial, prednisone did not improve live birth and was associated with concerning secondary safety signals.
Can I still become pregnant if no cause is found?
Yes. An unexplained unsuccessful transfer does not mean future transfers cannot work. ASRM specifically notes that after a careful review, further transfer may be reasonable rather than escalating to extensive unvalidated testing.
Sources
- American Society for Reproductive Medicine Practice Committee. American Society for Reproductive Medicine recurrent implantation failure: a committee opinion. Fertility and Sterility. 2026.
- ESHRE Working Group on Recurrent Implantation Failure. ESHRE good practice recommendations on recurrent implantation failure. Human Reproduction Open. 2023. doi:10.1093/hropen/hoad023.
- Human Fertilisation and Embryology Authority. Immunological tests and treatments for fertility. Current patient evidence review.
- Sun Y, Cui L, Lu Y, et al. Prednisone vs placebo and live birth in patients with recurrent implantation failure undergoing in vitro fertilization. JAMA. 2023;329(17):1460–1468. doi:10.1001/jama.2023.5302.
- Almohammadi A, Choucair F, Khan KS, et al. Interventions for recurrent embryo implantation failure: an umbrella review. International Journal of Gynecology & Obstetrics. 2025;169(2):539–556. doi:10.1002/ijgo.16066.
- Incognito GG, Pittana E, Cimadomo D, et al. Immunological interventions in recurrent implantation failure: a systematic review and SWOT analysis. Minerva Obstetrics and Gynecology. 2026;78(2):130–141. doi:10.23736/S2724-606X.25.05657-X.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.